{"id":4137,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/lercanidipine-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"lercanidipine-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/lercanidipine-hydrochloride-txt\/","title":{"rendered":"Lercanidipine hydrochloride.txt"},"content":{"rendered":"

Lercanidipine hydrochloride <\/h1>\n

CLINICAL USE <\/H3>
\nCalcium-channel antagonist:Mild to moderate hypertension

DOSE IN NORMAL RENAL FUNCTION <\/H3>
  • 10 to 20 &nbsp &nbsp : mg daily

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :648.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50 (as metabolites)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :8\u201310\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Use small doses and titrate to response
  • 10 to 20 &nbsp &nbsp : Use small doses and titrate to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use small doses and titrate to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Antibacterials: avoid concomitant use with erythromycin\n
  • Anti-epileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone\n
  • Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole \u2013 avoid concomitant useAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers\n
  • Antivirals: concentration increased by ritonavir \u2013 avoid concomitant useCardiac glycosides: digoxin concentration increased\n
  • Ciclosporin: concentration of both drugs may be increased \u2013 avoid concomitant use\n
  • Grapefruit juice: concentration increased \u2013 avoid concomitant useTheophylline: possibly increased theophylline concentration

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Take before food

    OTHER INFORMATION <\/H4>Causes less peripheral oedema than other calcium-channel blockersLercanidipine hydrochloride.426 LETroZoLELetrozole
    \n

    CLINICAL USE <\/H3>
    \nTreatment of advanced breast cancer

    DOSE IN NORMAL RENAL FUNCTION <\/H3>2.5 mg daily

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :285.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 6<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.87<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :48\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Probably dialysed. Use with caution<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Use with caution
  • HDF\/high flux &nbsp :Dialysed. Use with caution
  • CAV\/VVHD &nbsp &nbsp &nbsp:Probably dialysed. Use with caution

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • None known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013.
    \n","protected":false},"excerpt":{"rendered":"

    Lercanidipine hydrochloride CLINICAL USE Calcium-channel antagonist:Mild to moderate hypertension DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4137","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4137"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4137\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}